The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide (Byetta, Bydureon BCise), liraglutide (Saxenda, Victoza), and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative fasting.
MECHANISM — GLP-1 receptor agonists and...
- Elafibranor (Iqirvo) for Primary Biliary Cholangitis
- Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
- Clonidine Oral Suspension (Onyda XR) for ADHD
- Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
- In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)
- Antiviral Drugs for Seasonal Influenza for 2024-2025
- Marstacimab (Hympavzi) for Hemophilia A and B
- In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
- Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
- Isatuximab (Sarclisa) for Multiple Myeloma (online only)
- Ribociclib (Kisqali) for Early Breast Cancer (online only)
- Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)
RELEASE
The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration (AMD) who have best-corrected visual acuity (BCVA) of 20/32 to 20/70.
DRY AMD — About 90% of patients with AMD have the dry (non-neovascular) form, which is characterized by abnormalities of the retinal pigment epithelium with focal accumulation of metabolic byproducts known as drusen. Patients with dry AMD may experience a slow reduction in central vision. Geographic atrophy (GA) is an advanced form of dry AMD that is associated with progressive and irreversible loss of the retinal pigment epithelium, photoreceptors, and the underlying choriocapillaris. Patients with GA may have difficulty driving, reading, and seeing in low light and can …